Inspire Medical Systems reduces FY23 revenue outlook, blames slow commercial launch.

• Inspire Medical Systems reports Q2 financial results • Revenue outlook reduced to $900-$910 million • Diluted net income per share reduced to $0.40-$0.50 • Slower-than-expected commercial launch of next generation Inspire model • Pomerantz LLP investigating potential securities fraud • Investors advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980

Inspire Medical Systems (NYSE: INSP), a leading provider of sleep apnea treatment implants, has reaffirmed its updated 2025 financial guidance following its Q2 results. The company significantly reduced its full-year revenue outlook to $900 million - $910 million and diluted net income per share to $0.40 - $0.50, citing slower-than-expected uptake of its next-generation device, the Inspire V [1].

The company's stock price fell $42.04 per share, or 32.35%, to close at $87.91 on August 5, 2025, following the announcement [1]. Inspire Medical Systems also announced that its Chief Financial Officer, Rick Buchholz, will step down at the end of 2025 and transition to a financial advisory role until February 2026 [3].

Pomerantz LLP, a prominent securities litigation firm, has initiated an investigation into potential claims on behalf of investors of Inspire Medical Systems. The investigation focuses on whether the company and its officers and/or directors have engaged in securities fraud or other unlawful business practices [2]. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information about the investigation [2].

Inspire Medical Systems' reaffirmation of its full-year 2025 financial guidance signals operational confidence during a period of executive transition. The maintained guidance suggests that the company sees current executive transitions as manageable in the context of ongoing business objectives [3].

References:
[1] https://seekingalpha.com/news/4489337-inspire-medical-reaffirms-updated-2025-guidance
[2] https://www.ainvest.com/news/inspire-medical-systems-reduces-fy23-revenue-outlook-900mln-910mln-2508/
[3] https://finance.yahoo.com/news/did-cfo-transition-reaffirmed-outlook-101442119.html